RIGL Stock Analysis: Buy, Sell, or Hold?
RIGL - Rigel Pharmaceuticals Inc. (New)
$27.45
-0.05 (-0.18%)
▼
5d:
+4.1%
30d:
-7.36%
90d:
-35.91%
BUY
HIGH Confidence
Analysis Updated: Apr 2, 2026 12:00 AM ET
Earnings: May 05, 2026
Smart Money Accumulation
RIGL is down 9.9% this week, but smart money is accumulating calls. Top strike: $29 2026-04-17 with 17 OI. Call ratio: 77% View Scanner →
Strength: 7.6/10
Get Alerted When RIGL Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: RIGL appears deeply undervalued. Market expects -13.1% annual earnings decline despite 1599% recent earnings growth. Contrarian opportunity at discount to historical valuation.
✅ BUY SIGNAL: RIGL appears deeply undervalued. Market expects -13.1% annual earnings decline despite 1599% recent earnings growth. Contrarian opportunity at discount to historical valuation.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$39.05
Based on -1.2% avg growth
INTRINSIC VALUE TODAY
$24.24
Trading above fair value
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 8.7x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: RIGL is currently trading at $27.45, which is considered fair relative to its 30-day fair value range of $25.39 to $32.20. From a valuation perspective, the stock is trading at a discount (Forward PE: 5.7) compared to its historical average (8.7). Remarkably, the market is currently pricing in an annual earnings decline of 13.1% over the next few years. This pessimistic expectation contrasts with the company's recent 1598.7% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, RIGL is in a strong downtrend. The price is approaching resistance at $28.23. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: RIGL has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. In the options market, Implied Volatility is low (21th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $51.20 (+86.2%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, RIGL is in a strong downtrend. The price is approaching resistance at $28.23. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: RIGL has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. In the options market, Implied Volatility is low (21th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $51.20 (+86.2%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
FAIR
Fair Price Range
$25.39 -
$32.20
Company Quality Score
60/100
(BUY)
Options IV Signal
21th percentile
(LOW)
Volume Confirmation
HIGH
Confidence Score
86.5%
All Signals
- NEUTRAL: Price in fair range
- BULLISH: Options cheap (IV 21th percentile)
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 86.2% below Wall St target ($51.20)
Fair Price Analysis
30-Day Fair Range
$25.39 -
$32.20
Current vs Fair Value
FAIR
Expected Move (7 Days)
±$4.03
(14.7%)
Support & Resistance Levels
Support Level
$25.07
Resistance Level
$28.23
Current Trend
Strong Downtrend
Technical data as of
Apr 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
5.73
Wall Street Target
$51.20
(+86.2%)
Revenue Growth (YoY)
21.2%
Earnings Growth (YoY)
1598.7%
Profit Margin
124.7%
Valuation Discount vs History
-13.1% cheaper
PE vs Historical
5.7 vs 8.7
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-13.1%
(market-implied from PE analysis)
1-Year Target
$24.75
(-10%)
2-Year Target
$22.27
(-19%)
3-Year Target
$20.05
(-27%)
3-Yr Target (if PE normalizes)
(PE: 6→9)
$30.42
(+11%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 22.4, Growth: -6.5%)
$106.99
(+289%)
Base:
(SPY PE: 5.7, Growth: -6.5%)
$27.45
(0%)
Bear:
(PE: 4.9, Growth: -6.5%)
$23.33
(-15%)
📈
Valuation based on Current Earnings
Trailing PE: 1.33 | Current EPS (TTM): $19.48
Bull Case
$14.28
(-46%)
Analyst growth -50.0%, PE expands to 1.5
Base Case
$12.98
(-51%)
Market implied -50.0%, PE stable at 1.3
Bear Case
$17.65
(-33%)
Severe decline -20.0%, PE contracts to 1.1
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 5.7 to 8.7
Stabilization Target:
$41.73
(+51.7%)
PE Expansion Potential:
+51.7%
Share & Embed Analysis
Last updated: April 02, 2026 3:12 PM ET
Data refreshes hourly during market hours. Next update: 4:12 PM
Data refreshes hourly during market hours. Next update: 4:12 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is RIGL showing a specific setup today?
Insider Activity (6 Months)
0
Buys
1
Sells
Net
INSIDERS SELLING
Recent Transactions
Walter H Moos
SELL
4000 shares
2026-02-20
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$89 | 65 BUY |
|
SRPT
Sarepta Therapeutics Inc |
STRONG BUY
26 analysts |
$21 | 56 HOLD |
|
LEGN
Legend Biotech Corp |
STRONG BUY
22 analysts |
$58 | 57 HOLD |
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$84 | 61 BUY |
|
VRTX
Vertex Pharmaceuticals I… |
BUY
34 analysts |
$547 | 50 HOLD |
Advanced RIGL Option Strategies
Professional options setups generated by AI based on today's RIGL price and gamma walls.
